ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia

Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men

AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients

The submission is supported by positive results from the Phase 3 AMPLIFY trial

Roche’s Susvimo maintains vision over five years

Revvity launches reagent technology for targeted therapeutics

Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research

Eli Lilly inaugurates global capability centre in hyderabad to advance AI initiatives

The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery

Cellipont and CellVax expand partnership to advance manufacturing of immunotherapy for GI cancers

The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product

Sanofi’s GPRC5D monoclonal antibody earns ODD in US for multiple myeloma

Sandoz to acquire Just–Evotec Biologics facility for $300 million

The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes

FDA restrict 7-OH opioid products to protect consumers

7-OH is a concentrated byproduct of the kratom plant and has shown potential for abuse by binding to opioid receptors

Johnson & Johnson submits additional data to FDA on psoriatic arthritis

The submission is supported by results from the Phase 3b APEX study